ImageneBio (Nasdaq: IMA) announced inducement equity grants on March 16, 2026 to two newly hired employees under its 2025 Inducement Plan. The grants total 38,442 RSUs and 43,000 NSOs with NSO exercise price set at $6.20 per share.
The NSOs vest over four years (25% at one year, then monthly over 36 months). RSUs vest in equal annual installments over four years. Awards are subject to the 2025 Inducement Plan and individual award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
Key Figures
RSUs granted:38,442 RSUsNSOs granted:43,000 NSOsNSO exercise price:$6.20 per share+4 more
7 metrics
RSUs granted38,442 RSUsEmployment inducement awards under 2025 Inducement Plan
NSOs granted43,000 NSOsEmployment inducement awards under 2025 Inducement Plan
NSO exercise price$6.20 per shareExercise price equal to March 16, 2026 closing price
NSO vesting period4 yearsNon-qualified stock options vest over four years
Initial NSO vesting25% at 1 yearFirst tranche vests on one-year anniversary of vesting start
Remainder NSO vesting75% over 36 monthsRemaining shares vest monthly over following 36 months
RSU vesting period4 yearsRSUs vest in equal annual installments over four years
Market Reality Check
Price:$6.02Vol:Volume 9,589 is well belo...
low vol
$6.02Last Close
VolumeVolume 9,589 is well below the 20-day average 35,358 (relative volume 0.27).low
TechnicalShares traded below the 200-day moving average of 8.56, indicating a weaker longer-term trend.
Peers on Argus
Peer biotech names showed mixed moves, with some up and others down, and scanner...
2 Up1 Down
Peer biotech names showed mixed moves, with some up and others down, and scanner data flags no coherent sector-wide momentum tied to this headline.
Outlined participation in multiple Q4 2025 healthcare conferences.
Pattern Detected
Recent news on earnings, conferences and management changes generally coincided with modest single-digit moves, mostly positive, with one divergence on a CMO appointment.
Recent Company History
Over the past few months, ImageneBio has reported earnings updates, investor conference participation, and management changes. On Nov 12, 2025, it combined Q3 results with merger and financing news. Subsequent items included conference appearances on Nov 6, 2025 and Feb 26, 2026, a new Chief Medical Officer on Feb 10, 2026, and Q4/full-year 2025 results on Mar 10, 2026. Today’s inducement grants fit into this pattern of ongoing corporate and personnel-related updates.
Market Pulse Summary
This announcement details equity inducement awards totaling 38,442 RSUs and 43,000 NSOs under a 2025...
Analysis
This announcement details equity inducement awards totaling 38,442 RSUs and 43,000 NSOs under a 2025 Inducement Plan for new hires, with a $6.20 exercise price and four-year vesting. It follows a series of corporate updates, including earnings and management changes, and reflects continued investment in building the team. Investors may watch how such grants impact share-based compensation levels and potential dilution over time.
"granted equity awards to two newly hired employees in the form of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
non-qualified stock optionsfinancial
"and non-qualified stock options (“NSOs”) for an aggregate of 38,442 RSUs"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
Nasdaq Listing Rule 5635(c)(4)regulatory
"as an inducement material to their acceptance of employment ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"Each NSO has an exercise price equal to $6.20 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"The NSOs will vest over four years, with 25% of the shares vesting on the one-year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. Not financial advice.
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on March 16, 2026 the Company’s Compensation Committee of the Board of Directors (the “Compensation Committee”) granted equity awards to two newly hired employees in the form of restricted stock units (“RSUs”) and non-qualified stock options (“NSOs”) for an aggregate of 38,442 RSUs and 43,000 NSOs as an inducement material to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The employment inducement awards were granted under the Company’s 2025 Inducement Plan.
Each NSO has an exercise price equal to $6.20 per share, the closing price on March 16, 2026. The NSOs will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months subject to the grantee’s continued service through each vesting date. The RSUs will vest over four years, with equal installments vesting annually beginning on the one-year anniversary of the vesting commencement date subject to the grantee’s continued services through each vesting date. The equity awards are subject to the terms and conditions of the Company’s 2025 Inducement Plan and the terms and conditions of the applicable equity award agreement covering such grant.
About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, IMG-007, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.
What did ImageneBio (IMA) announce about inducement grants on March 16, 2026?
ImageneBio granted inducement awards of RSUs and NSOs to two new hires on March 16, 2026. According to the company, the aggregate grants were 38,442 RSUs and 43,000 NSOs under the 2025 Inducement Plan, issued to induce acceptance of employment.
How many RSUs and NSOs did ImageneBio (IMA) grant and under which plan?
ImageneBio granted an aggregate of 38,442 RSUs and 43,000 NSOs under its 2025 Inducement Plan. According to the company, the awards were granted as inducements material to the new hires' acceptance of employment.
What is the exercise price and vesting schedule for the IMA NSOs granted March 16, 2026?
The NSOs have an exercise price of $6.20 per share, equal to the March 16, 2026 closing price. According to the company, NSOs vest over four years with 25% at one year and the remainder monthly over 36 months.
How do the RSUs awarded by ImageneBio (IMA) vest over time?
The RSUs vest over four years in equal annual installments beginning on the one-year anniversary. According to the company, vesting is subject to continued service through each applicable vesting date.
Are the inducement awards for ImageneBio (IMA) subject to additional terms or agreements?
Yes. The awards are subject to the terms of the company's 2025 Inducement Plan and individual equity award agreements. According to the company, each grant is governed by those plan terms and applicable award agreement conditions.
